Actively Recruiting
A Study of GR1803 in Systemic Lupus Erythematosus
Led by Genrix (Shanghai) Biopharmaceutical Co., Ltd. · Updated on 2026-03-10
44
Participants Needed
1
Research Sites
95 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
to evaluate the safety and efficacy of GR1803 in the treatment of patients with systemic lupus erythematosus
CONDITIONS
Official Title
A Study of GR1803 in Systemic Lupus Erythematosus
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Confirmed diagnosis of systemic lupus erythematosus
- SLEDAI-2K score of 6 or higher
- Written informed consent and ability to comply with protocol requirements
- Received adequate doses of glucocorticoids, antimalarials, or immunosuppressants for at least 3 months
You will not qualify if you...
- Presence of unstable acute or chronic diseases
- Active infection
- History of malignant tumor within the past 5 years
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China, 430000
Actively Recruiting
Research Team
N
Nian
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here